secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001558370-25-006602
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Q1 product rev $37.7M; Phase 3 HO trial meets endpoint with -19.8% BMI reduction
--------------------------------------------------------------------------------

- Net product revenue $37.7M, up from $26.0M YoY; U.S. $24.5M, ex-U.S. $13.2M.
- Net loss $50.8M ($0.81 per share) vs $141.4M ($2.35) YoY; R&D down due to prior-year acquisition cost.
- Phase 3 TRANSCEND trial met primary endpoint: -19.8% placebo-adjusted BMI reduction at 52 weeks (p<0.0001); no new safety signals.
- Cash and investments $314.5M as of March 31, 2025; cash runway into 2027.
- Fiscal 2025 Non-GAAP operating expense guidance $285M-$315M; regulatory submissions for HO in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/0001558370-25-006602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer